Antibodies

RO5458640 (anti-TNFSF12) is a humanized monoclonal antibody directed against the apoptotic ligand TNF-like weak inducer of apoptosis (TWEAK) with potential antineoplastic activity. It is used to treat renal interstitial fibrosis.

RO5458640 (anti-TNFSF12) is a humanized monoclonal antibody directed against the apoptotic ligand TNF-like weak inducer of apoptosis (TWEAK) with potential antineoplastic activity. It is used to treat renal interstitial fibrosis.

RO5458640 (anti-TNFSF12) is a humanized monoclonal antibody directed against the apoptotic ligand TNF-like weak inducer of apoptosis (TWEAK) with potential antineoplastic activity. It is used to treat renal interstitial fibrosis.

RO5458640 (anti-TNFSF12) is a humanized monoclonal antibody directed against the apoptotic ligand TNF-like weak inducer of apoptosis (TWEAK) with potential antineoplastic activity. It is used to treat renal interstitial fibrosis.

Sutimlimab (anti-C1s), a first-in-class complement protein component 1, s subcomponent (C1s) inhibitor, can be used for the research of cold agglutinin disease. C1s is a serine protease which cleaves C4 and C2 to form the C3

Tafasitamab (anti-CD19) is an Fc-modified, humanized monoclonal antibody that binds to the human B-cell surface antigenCD19.Purity&gt95% (SDS-PAGE&ampSEC)Endotoxin Level&lt 0.01EU/μg

Urelumab is a humanized IgG4 monoclonal antibody used as a CD137 agonist to enhance the antitumor activity of T cells and natural killer cells, and to enhance the cytotoxic activity of Rituximab. Urelumab can be used in studies of diffuse large

PurityUtomilumab is a humanized IgG2 mAb agonist that targets the T-cell co-stimulatory receptor 4-1BB/CD137. Utomilumab can be used in relapsed/refractory follicular lymphoma (FL) and other CD20+ non-Hodgkin lymphoma (NHL) studies.&gt95%

VGX100 (anti-VEGFC) is a fully human monoclonal antibody targeting the human vascular endothelial growth factor C (VEGFC or Flt4 ligand) with potential antiangiogenic activity and lymphangiogenesis. It also prevent metastasis.

VGX100 (anti-VEGFC) is a fully human monoclonal antibody targeting the human vascular endothelial growth factor C (VEGFC or Flt4 ligand) with potential antiangiogenic activity and lymphangiogenesis. It also prevent metastasis.

VGX100 (anti-VEGFC) is a fully human monoclonal antibody targeting the human vascular endothelial growth factor C (VEGFC or Flt4 ligand) with potential antiangiogenic activity and lymphangiogenesis. It also prevent metastasis.

VGX100 (anti-VEGFC) is a fully human monoclonal antibody targeting the human vascular endothelial growth factor C (VEGFC or Flt4 ligand) with potential antiangiogenic activity and lymphangiogenesis. It also prevent metastasis.